The role of G-CSF in the treatment of advanced tumors

Bottoni, Ugo; Trapasso, Francesco

doi:10.4161/cbt.8.18.9453

Cited by 6 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from neutrophils, cells such as tumor cells [24], Th17 cells [40], γβ T cells [84], B cells [85], lymphocytes, and macrophages [13] present in the tumor microenvironment secrete regulatory factors to facilitate cancer progression. As discussed previously, the proliferation and maturation of neutrophils in bone marrow requires cytokines and chemokines such as G-CSF [86], CXCR2 chemokines, and IL17. Multiple cell types in the tumor microenvironment contribute to the pool of G-CSF, CXCR2 ligands, and IL17.…”

Section: Functions Of Neutrophils In the Tumor Microenvironmentmentioning

confidence: 99%

Tumor-Associated Neutrophils in Cancer: Going Pro

Saxena

Awaji

et al. 2019

Cancers

259

236

View full text Add to dashboard Cite

The progression of cancer is not only about the tumor cell itself, but also about other involved players including cancer cell recruited immune cells, their released pro-inflammatory factors, and the extracellular matrix. These players constitute the tumor microenvironment and play vital roles in the cancer progression. Neutrophils—the most abundant white blood cells in the circulation system—constitute a significant part of the tumor microenvironment. Neutrophils play major roles linking inflammation and cancer and are actively involved in progression and metastasis. Additionally, recent data suggest that neutrophils could be considered one of the emerging targets for multiple cancer types. This review summarizes the most recent updates regarding neutrophil recruitments and functions in the tumor microenvironment as well as potential development of neutrophils-targeted putative therapeutic strategies.

show abstract

Section: Functions Of Neutrophils In the Tumor Microenvironmentmentioning

confidence: 99%

Tumor-Associated Neutrophils in Cancer: Going Pro

Saxena

Awaji

et al. 2019

Cancers

259

236

View full text Add to dashboard Cite

show abstract

“…Other immune cell population present in the tumor microenvironment, such as macrophages [80], lymphocytes [80] (including Th17 cells [81] and y8 T cells [66]), B cells [82], are also known to secrete tumor-promoting factors. As discussed previously, the proliferation and maturation of neutrophils in bone marrow require cytokines and chemokines such as G-CSF [83]. CXCR2 chemokines, and IL17.…”

Section: Neutrophil-secreted Cytokines and Chemokinesmentioning

confidence: 87%

Neutrophils in the Tumor Microenvironment

Saxena

Singh

2020

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Neutrophils are the first responders to inflammation, infection, and injury. As one of the most abundant leukocytes in the immune system, neutrophils play an essential role in cancer progression, through multiple mechanisms, including promoting angiogenesis, immunosuppression, and cancer metastasis. Recent studies demonstrating elevated neutrophil to lymphocyte ratios suggest neutrophil as a potential therapeutic target and biomarker for disease status in cancer. This chapter will discuss the phenotypic and functional changes in the neutrophil in the tumor microenvironment, the underlying mechanism(s) of neutrophil facilitated cancer metastasis, and clinical potential of neutrophils as a prognostic/diagnostic marker and therapeutic target.

show abstract

“…Granulocyte colony-stimulating factor therapy is successfully used in oncology for the treatment of several advanced neoplasms. Granulocyte colony-stimulating factor or GM-CSF therapies are used for in the following treatments: (1) to treat patients with advanced metastatic disease after chemotherapy to treat or prevent neutropenia, and also in bone marrow transplantation to help to recover from the bone marrow depression induced by chemotherapy [10]; (2) in conjunction with chemotherapy to treat patients with advanced breast carcinoma [11]; (3) to promote the acceleration of myeloid recovery in patients with non-Hodgkin's lymphoma, acute lymphoblastic leukemia, and Hodgkin's disease undergoing autologous stem cell transplantation [2]; (4) to treat brain tumor cells [11]; (5) to treat autoimmune diseases such as inflammatory bowel disease (IBD), Crohn disease and ulcerative colitis [12]; (6) to accelerate myeloid recovery in patients undergoing stem cell transplantation [2]. Granulocyte colony-stimulating factor is also used to decrease the inci-dence of infection in patients with non-myeloid malignancies [2].…”

Section: Introductionmentioning

confidence: 99%

“…Production of granulocyte colony-stimulating factor or granulocyte-macrophage colonystimulating factor loaded liposomes Liposomes were produced by the hand-shaking method [22]. Due to the previously observed strong cytotoxic effect of positive-charge and neutral-charge liposomes on all types of tested cells, only negative-charge liposomes were selected for cytokine encapsulation experiments [11].…”

Section: Introductionmentioning

confidence: 99%

Encapsulation of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in liposomes prepared by thin film hydration and their transfer to mesenchymal stem cells and cord blood hematopoietic stem cells

et al. 2020

View full text Add to dashboard Cite

IntroductionCytokines are important immune modulator factors controlling homeostasis of the body and are involved in tissue regeneration after wound healing. The encapsulation of cytokines in liposomes has many advantages potentially useful for their transfer to the cells. Liposomes protect cytokines from neutralization, improving their pharmacokinetics or biologic activity in vivo. They are targeted to specific cell types and may delay the release of cytokines, allowing their sustained paracrine delivery. Their physicochemical characteristics such as size, shape, charge, and stability are important parameters improving bio-distribution and prolonged pharmacokinetics of encapsulated cytokines.Material and methodsWe developed an efficient protocol for the encapsulation of two types of cytokines, granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF), in liposomes that can be stored long term in the active state.ResultsThis method allows for the encapsulation of 12–13% of the total amount of cytokines and 50% of encapsulated cytokines are entrapped in liposomes of more than ≤ 600 nm in diameter. We show that in the studied cell lines the liposome-encapsulated cytokines do not affect cell morphology, proliferation or mortality.ConclusionsThe G-CSF or GM-CSF can be delivered to the cells in working concentrations through the encapsulation in the liposomes. Before the clinical application, the efficiency of these liposomes should be confirmed by an in vivo study.

show abstract

The role of G-CSF in the treatment of advanced tumors

Cited by 6 publications

References 25 publications

Tumor-Associated Neutrophils in Cancer: Going Pro

Tumor-Associated Neutrophils in Cancer: Going Pro

Neutrophils in the Tumor Microenvironment

Encapsulation of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in liposomes prepared by thin film hydration and their transfer to mesenchymal stem cells and cord blood hematopoietic stem cells

Contact Info

Product

Resources

About